- Home
- DFDV vs SCPH Comparison
DFDV vs SCPH Comparison
Compare DFDV & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFDV
- SCPH
- Stock Information
- Founded
- DFDV 2018
- SCPH 2013
- Country
- DFDV United States
- SCPH United States
- Employees
- DFDV N/A
- SCPH N/A
- Industry
- DFDV Finance: Consumer Services
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- DFDV Finance
- SCPH Health Care
- Exchange
- DFDV Nasdaq
- SCPH Nasdaq
- Market Cap
- DFDV 330.2M
- SCPH 299.0M
- IPO Year
- DFDV N/A
- SCPH 2017
- Fundamental
- Price
- DFDV $15.79
- SCPH $5.67
- Analyst Decision
- DFDV Buy
- SCPH Buy
- Analyst Count
- DFDV 1
- SCPH 3
- Target Price
- DFDV $45.00
- SCPH $12.00
- AVG Volume (30 Days)
- DFDV 2.3M
- SCPH 1.5M
- Earning Date
- DFDV 11-05-2025
- SCPH 11-12-2025
- Dividend Yield
- DFDV N/A
- SCPH N/A
- EPS Growth
- DFDV N/A
- SCPH N/A
- EPS
- DFDV 1.17
- SCPH N/A
- Revenue
- DFDV $3,520,660.00
- SCPH $49,969,000.00
- Revenue This Year
- DFDV $70.03
- SCPH $104.30
- Revenue Next Year
- DFDV $142.86
- SCPH $76.06
- P/E Ratio
- DFDV $13.47
- SCPH N/A
- Revenue Growth
- DFDV 97.13
- SCPH 107.79
- 52 Week Low
- DFDV $0.49
- SCPH $1.94
- 52 Week High
- DFDV $53.88
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- DFDV 47.47
- SCPH 64.40
- Support Level
- DFDV $14.93
- SCPH $5.64
- Resistance Level
- DFDV $16.35
- SCPH $5.65
- Average True Range (ATR)
- DFDV 1.05
- SCPH 0.03
- MACD
- DFDV 0.00
- SCPH -0.02
- Stochastic Oscillator
- DFDV 29.98
- SCPH 75.00
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.